HealthNet

2021: Ministry of Industry and Trade issued grants of 1.3 billion rubles for medical technology projects

The competition commission Ministry of Education and Science Russia summed up the selection results for the provision of grants state to support competence centers on the NTI basis of institutions of higher formations and scientific organizations. The winners included medical projects of the Federal Research Center "Fundamental Foundations of Biotechnology" Russian Academy of Sciences and Samara State Medical University (), SamSMU the press service of the department reported on November 20, 2021.

The STI Competence Center in the direction of "Molecular Engineering in the Life Sciences" will be opened on the basis of the Federal Research Center "Fundamental Foundations of Biotechnology." The center will develop technologies and create platforms for molecular engineering of new express diagnostic systems, new generation food products, drugs and bio-additives. Among the industrial partners of the center are Efko Group of Companies, OKhK Uralchem JSC, Generium JSC. The main STI markets that await the development of the center will be Fudnet and Helsnet.

According to the results of the selection, the Center of Competence of the STI in the direction "Bionic Engineering in Medicine" will launch the Samara State Medical University of the Ministry of Health of Russia. The center's team will create bionic technologies, including for digital modeling of artificial tissues, organs and body parts, the creation of complex endoprostheses and exoprostheses, and the development of personal medical assistants. The consortium of the center included Schwabe LLC, Motorica JSC, 3D Bioprinting Solutions and many others. The main STI markets interested in the center's activities are Helsnet and Neuronet.

The fact that "bionic engineering in medicine" and "molecular engineering in the life sciences" will be included in STI became known in July 2021. Then the interdepartmental working group on the development and implementation of STI decided to expand the list of "end-to-end technologies" that represent key scientific and technical areas. Their development, according to the Government of the Russian Federation, will create globally competitive high-tech products and services.^[1]

2017

Roadmap HealthNet approved

The Presidential Council for Modernization and Innovative Economic Development approved the Healthnet roadmap in March. Healthnet refers to an open ecosystem that supports and develops companies that create, produce and provide biotechnological and medical products and services that significantly improve human health and quality of life in Russia and the world.

The roadmap describes the development of the Healthnet direction until 2035. The document was prepared as part of the National Technology Initiative (STI) project, launched at the initiative of Russian President Vladimir Putin^[2].

The authors of the roadmap are First Deputy Minister of Health Igor Kagramazyan and Chairman of the Board of Directors of R-Farm Alexey Repik.

Trends in medicine and prospects of Russian companies

The main trends in medicine are: personalization, wearable medical devices, gene technologies (with their help "superorganisms" can be created), bioprosthesis (including 3D bioprinters), preventive medicine (treatment of diseases at an early stage), "active aging" and naturopotic methods of treatment.

The key advantages of Russian companies in the Healthnet market are: high research potential of Russian companies, wide opportunities for research (loyal attitude to the use of living organisms in medical research, a wide variety of ethnic and racial differences), experience in the development of world-class applied software, organization of databases, experience in the use of big data, the presence of environmentally friendly diverse natural and climatic zones for growing medicinal plants.

However, there are also restrictions on the development of Russian companies, namely: insufficient interdisciplinary technological directions, imported equipment, the lack of uniform standards for engineering and synthetic biology, the lack of highly professional personnel (biotechnologists, biochemists, pharmacologists).

Volumes of Russian and international markets

The global health market accounts for 10% of global GDP and grows by 5.2% per year. By 2018, it will amount to $9.3 trillion. Healthnet's share of the global market is 10% ($0.9 trillion). By 2020, the share of Healthnet will increase to 19.6% ($1.97 trillion), by 2035 - to 58.8% and will amount to more than $9 trillion.

The Russian market for Healthnet goods and services accounts for 1.4% of the world ($13.9 billion). By 2035, the share of the Russian market will be 3.58% ($310 billion) of the entire world market. In monetary terms, the total effect of implementing the measures laid down in the roadmap will amount to 3.89 trillion rubles by 2035. Including the economic effect in the form of improving health indicators will amount to 1.98 trillion rubles, the commercial effect - 1.17 trillion rubles, attracted investments - 738 billion rubles.

Healthnet Roadmap Targets

According to the roadmap targets, the revenue of Russian Healthnet companies will grow from $6.1 billion in 2016 to $106.5 billion in 2035. The share of Russian companies in the global health market will increase from 0.6% to 3%, and the share of Russian Healthnet companies in the corresponding world market - from 7.8% to 57%. The number of technological Russian companies in the field of Healthnet will grow from 4 thousand to 21 thousand, the number of issued international patents will increase from 517 to 11.4 thousand.

Budget will save on pension expenses

The number of companies in the Russian Healthnet market by 2035, having a capitalization of more than $5 million and created no earlier than 2015, will be 408. Coverage of preventive medicine will increase from 6% to 50%. In the Sport and Recreation segment, the share of products produced in Russia will increase from 10% to 40%, and the share of Russian companies in the market for medical software and personal medical devices will increase from 30% to 80%.

In addition, through the road map, the country's economy will benefit from a number of factors, including savings in the Compulsory Health Insurance Fund and a reduction in the cost of the Pension Fund due to the potential expansion of the age range of working life and working life.

According to the results of the implementation of the roadmap, at least 300 thousand new jobs will be created in Russia (paramedic instructors, medical consultants on health-saving technologies, general practitioners), and due to the revival of medicinal crop production in the agro-complex - another 1 million jobs.

Big Data in Medicine

The activities of the road map are divided into six segments. The IT in Medicine segment involves the design and implementation of devices and services for monitoring and correcting human health. An important area in this area is the development of medical information systems that automate the activities of medical organizations, automation of doctors' workplaces and their connection to unified regional and federal information systems.

In the IT in Medicine segment, it is planned to develop decision support systems (SPRs) using big data algorithms for local use in medical organizations when providing remote medical services for diseases and the high risk of their development as prescribed by a doctor. It is also planned to develop a line of non-invasive personal telemedicine devices (PTP), including those based on new physical and biological principles of diagnostics and therapeutic and diagnostic home modules, organize their production in Russia and introduce SIM cards for their use.

In addition, a line of electronic health passports (IMEC) should be developed, containing, among other things, genetic information about patients. During 2017-2025, the full implementation of electronic passports will be carried out, medical organizations of all forms of ownership will provide patient medical history data to the IEMC and receive the necessary patient medical history data from them.

The total effect of the implementation of roadmap measures in the IT in medicine segment will be 1.7 trillion rubles. by 2035. Russian products in this segment by 2035 will amount to at least 5% of the global market.

Engineering Bioconstructor

The Biomedicine segment is a market for personalized medicine, new medical materials, bioprostheses, artificial organs. The segment consists of developers, manufacturers and distributors of products based on the use of biologics or technologies for therapy and molecular biological diagnostics.

The products of the segment are therapeutic monoclonal antibodies, oncolytic viruses, vaccines, as well as production technologies for their synthesis, kits and complexes for PCR diagnostics, sequencing and laboratory mass spectrometry.

In the Biomedicine segment, new technologies will be created in the following areas: regenerative medicine and cellular engineering; biologics, polyvalent gene engineering vaccines and targeted drugs; modification of pro- and eukaryotic cells; obtaining and processing omics data; development, production and use of personalized medicines; additive medical technologies and immunobiological therapy of oncological diseases and chronic viral infection based on personalized cellular preparations.

A platform and technologies will also be created for the following purposes: antibiotic resistance control, network biobanks of tissues and cellular products (including the IT platform of the network infrastructure of biobanks), certified human and animal cell cultures and the Engineering Bioconstructor service platform. It is planned to develop non-invasive technologies and devices for analyzing the morphofunctional state of cell cultures using lifetime imaging methods, digital image processing software with the ability to analyze the quality and number of cells in the culture.

In the Biomedicine segment, the total effect will be 750 billion rubles. by 2035, the world market will grow from $186 billion in 2016 to $18 trillion in 2035. The Russian market in this segment will increase from $140 billion in 2016 to $2.4 billion in 2020 and to $95 billion in 2035. The volume of the Russian market in 2035 will be 3% of the global.

IT for longevity

The "Health and longevity" segment aims to extend the healthy life of a person and change the onset of diseases to a later date due to the results of research in the field of gerontology, geriatrics, genetics and biomedical technologies.

In the segment "Healthy longevity" it is planned to develop clinically reliable systems for diagnosing age-related changes and identify therapeutic targets for the prevention of age-related pathological changes and processes. During 2016-2035, the international community will adopt mechanisms for registering anti-aging therapeutics using the system of biomarkers of aging as a clinical target. From 2018, the development and integration of the IT platform for the analysis of knowledge in the field of healthy longevity will be carried out.

In the segment "Health and longevity," the total effect of the implementation of the roadmap will be 413 billion rubles. by 2035. The global market in this segment will increase from $186 billion in 2016 to $1.8 trillion in 2035. The Russian market for this period will increase from $140 million from 2016 to $2.4 billion in 2020 and to $95 billion in 2035. By 2035, the Russian market will be 3% of the world.

Sport and health

The segment "Sport and Health" includes the collection of information, processing, delivery to the consumer, the formation and implementation of corrective recommendations and measures, as well as the creation and implementation of a complex of new technological products - sports food, sports clothing, sports equipment, means of prevention, rehabilitation and rehabilitation.

In the segment "Sport and Health" will "conduct research in the field of interpretation of biometric data for athletes for the purpose and organization of training and health programs. It is planned to develop the Health Health software platform using Data Mining, Big Data and Machine Learning technologies and a software API for collecting data from Internet of Things devices. Also, data mining systems should be created, diagnostic complexes (SCANME AIC) should be installed and at least 35 regional incubators of medical and health technologies focused on sports of high achievements should be opened.

In the segment "Sport and Health" the total effect will be 148 billion rubles. The global market in this segment will grow from $55 billion in 2018 to $390 billion in 2035. The Russian market will grow from $3.66 billion in 2016 to $39.7 billion in 2035, the share of Russian products in the world market will be at least 10%.

Preventive medicine and the cultivation of medicinal plants

The "Preventive Medicine" segment helps to prevent the development of diseases, taking into account the individual approach to diagnosis, treatment and rehabilitation. A network of centers should be formed in the segment of "preventive medicine": by 2025, centers should appear in all regions of Russia, by 2035 - in all municipal districts.

Also, a database of interpretation of tests for auto-AT and elemental status should be developed based on the collection of thousands of samples of immunoreactivity profiles and elemental status of persons with different forms and stages of deviations from functional norms, SPPR in the field of preventive medicine (using evolutionary modeling technologies, a digital model of knowledge about human health and the properties of correction tools, processing large amounts of data and individual monitoring of functional state) and a holistic digital model of knowledge about human health and the properties of correction tools based on the theory of evolutionary modeling and class hypergraphs.

The authors of the document made a special emphasis on the cultivation of medicinal plants. The export of medicinal raw materials is much more profitable than the export of traditional Russian wheat, soybean and rapeseed, and the export of finished traditional herbal medicines made using modern technologies to the rapidly growing and stable markets of China, India and other East Asian countries, whose domestic development is significantly limited due to overpopulation and soil pollution, significantly increases its attractiveness.

To develop this area, it is necessary to amend the legislation for a simplified procedure for the circulation and registration of herbal medicines.

The authors of the document consider it necessary to rely on traditional Chinese medicine, complementing it with modern decision support systems (SPPR), individual devices for assessing the functional state in the concept of the corresponding direction of traditional medicine, information technologies for transmitting, storing and processing large amounts of information, telemedicine services for consulting citizens doctors on the peculiarities of the use of these methods and means. All this will make it easier and more accessible for citizens to apply the knowledge of traditional Chinese medicine in practice to preserve and improve their health.

In the segment "Preventive Medicine" the total effect will be 370 billion rubles. by 2035. The world market in this segment will grow from $265 billion in 2020 to $1.33 trillion in 2035. The Russian market will grow from $20 million in 2016 to $106.5 billion in 2035, the share of the Russian market will be at least 3% of the world.

IT Platform for Genetic Data Analysis

The Medical Genetics segment will develop projects to develop gene therapy drugs and gene therapy methods aimed at treating hereditary, oncological, cardiovascular and infectious diseases. Projects to create new molecular genetic diagnostics technologies for early detection, prevention and therapy of hereditary diseases. Projects to create IT platforms for bioinformation analysis of genomic and biomarker data, genomic data centers.

During the implementation of the roadmap measures, domestic personalized medicines and diagnostic services will be created. The total level of hereditary diseases by ethnic and geographical groups of the population has been established, a Russia database has been created on the structure of the gene pool and genomic variations in the population. Treatment of severe, socially significant and hereditary diseases will become more effective and cheap, the side effects of treatment will be significantly reduced, the export of medicinal gene therapies and substances will be established. Additional highly skilled jobs have been created.

It is also planned to develop new treatment methods using molecular genetic diagnostics technologies and organize a database on the structure of the gene pool and genomic variations of the population of Russia and a map of the expected frequency of hereditary diseases.

In the segment "Medical genetics" the total effect will be 510 billion rubles. by 2035. The world market in this segment will grow from $2.8 billion in 2016 to $1.15 trillion in 2035. The Russian market during this period will grow from $40 million to $9.3 billion, the share of the Russian market will be at least 3% of the world.

According to the expert calculations of the Institute of Health Economics of the Higher School of Economics, the implementation of the roadmap in the Medical Genetics segment will give the following effects: economic effect: 168 billion rubles; commercial effect: 143 billion rubles; investments: 200 billion rubles.

Among other effects, it is important to note:

• Reducing the cost of treating rare diseases by early detection;
• Optimization of medical and genetic consulting costs through the efforts of regional consultations in accordance with the identified level of genetic burden in the population of different regions;
• Increase of IVF procedure efficiency up to 60% (i.e. 60% of cycles will end with delivery of a healthy child) due to preimplantation diagnostics for chromosomal abnormalities;
• Increased number of babies born without abnormalities and monogenic diseases;
• The emergence of drugs aimed at increasing the effectiveness of the treatment of hereditary diseases.

Notes